Loading stock data…
$78.37+0.18 (+0.23%)
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Oruka Therapeutics, Inc. in the Healthcare sector is trading at $78.37 with a market capitalization of $6.2B. Wall Street consensus targets $155.00 (12 analysts), implying a +97.8% move over the next 12 months. The stock is currently 32% below its 52-week high of $115.52, remaining 18.9% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.11M↓ | -$36.43M↓ | -$34.43M↓ | -$34.10M↓ | -$28.43M |
| Net Income | -$41.21M↓ | -$31.82M↓ | -$29.58M↑ | -$30.28M↓ | -$24.57M |
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that t...